Matches in SemOpenAlex for { <https://semopenalex.org/work/W2654283350> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2654283350 abstract "e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy. We report results of the dose finding trial evaluating PVSRIPO delivered intratumorally by convection-enhanced delivery (CED). Methods: Eligible patients were adults with recurrent supratentorial WHO grade IV MG; solitary tumor 1-5.5cm in diameter; ≥4 weeks after chemotherapy, bevacizumab or study drug; adequate organ function; KPS≥70%; and positive anti-polio titer. The original two-step continual reassessment method dose escalation was amended to decrease to dose level(DL) -1 and DL -2 after observing prolonged steroid use in patients treated on higher DLs. Results: As of 2/01/2017, 52 pts were treated on study (1 each at DL1 and DL3, 7 at DL2, 2 at DL4, 4 at DL5, 24 at DL -1 and 13 at DL -2). Only one DLT was observed, a grade 4 intracranial hemorrhage at the time of catheter removal on DL5. Grade 3 or higher adverse events possibly, probably or definitely related to PVSRIPO include: lymphopenia (grade 3, n = 1), steroid myopathy (grade 3, n = 1), cerebral edema (grade 4, n = 1), headache (grade 3, n = 1), dystonia (grade 3, n = 1), pyramidal tract syndrome (grade 3, n = 6), seizure (grade 3, n = 1; grade 4, n = 1), delusions (grade 3, n = 1), hypertension (grade 3, n = 1), and thromboembolic events (grade 3, n = 2). At a median follow-up of 20.1 months, 20.8% of pts remain alive at 36-month post PVSRIPO infusion, compared to 4% of an historical control. Four pts remain alive more than 22 months post treatment without having received any additional intervention following PVSRIPO at 57.5+, 56.4+, 27.9+ and 23.2+ months. Conclusions: Infusion of PVSRIPO via CED is safe and encouraging efficacy results are observed. The dose finding study is now completed and we are initiating clinical trials evaluating combination of PVSRIPO with other therapies. Clinical trial information: NCT01491893." @default.
- W2654283350 created "2017-06-30" @default.
- W2654283350 creator A5002201007 @default.
- W2654283350 creator A5004814459 @default.
- W2654283350 creator A5006744691 @default.
- W2654283350 creator A5011590188 @default.
- W2654283350 creator A5036706523 @default.
- W2654283350 creator A5037596103 @default.
- W2654283350 creator A5043123379 @default.
- W2654283350 creator A5045697502 @default.
- W2654283350 creator A5046719798 @default.
- W2654283350 creator A5050271991 @default.
- W2654283350 creator A5057371623 @default.
- W2654283350 creator A5063349955 @default.
- W2654283350 creator A5064761966 @default.
- W2654283350 creator A5071832983 @default.
- W2654283350 creator A5081207160 @default.
- W2654283350 creator A5083472710 @default.
- W2654283350 creator A5085588522 @default.
- W2654283350 date "2017-05-20" @default.
- W2654283350 modified "2023-10-15" @default.
- W2654283350 title "Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG)." @default.
- W2654283350 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e13533" @default.
- W2654283350 hasPublicationYear "2017" @default.
- W2654283350 type Work @default.
- W2654283350 sameAs 2654283350 @default.
- W2654283350 citedByCount "0" @default.
- W2654283350 crossrefType "journal-article" @default.
- W2654283350 hasAuthorship W2654283350A5002201007 @default.
- W2654283350 hasAuthorship W2654283350A5004814459 @default.
- W2654283350 hasAuthorship W2654283350A5006744691 @default.
- W2654283350 hasAuthorship W2654283350A5011590188 @default.
- W2654283350 hasAuthorship W2654283350A5036706523 @default.
- W2654283350 hasAuthorship W2654283350A5037596103 @default.
- W2654283350 hasAuthorship W2654283350A5043123379 @default.
- W2654283350 hasAuthorship W2654283350A5045697502 @default.
- W2654283350 hasAuthorship W2654283350A5046719798 @default.
- W2654283350 hasAuthorship W2654283350A5050271991 @default.
- W2654283350 hasAuthorship W2654283350A5057371623 @default.
- W2654283350 hasAuthorship W2654283350A5063349955 @default.
- W2654283350 hasAuthorship W2654283350A5064761966 @default.
- W2654283350 hasAuthorship W2654283350A5071832983 @default.
- W2654283350 hasAuthorship W2654283350A5081207160 @default.
- W2654283350 hasAuthorship W2654283350A5083472710 @default.
- W2654283350 hasAuthorship W2654283350A5085588522 @default.
- W2654283350 hasConcept C104317684 @default.
- W2654283350 hasConcept C159047783 @default.
- W2654283350 hasConcept C203014093 @default.
- W2654283350 hasConcept C2522874641 @default.
- W2654283350 hasConcept C2778227246 @default.
- W2654283350 hasConcept C2779278377 @default.
- W2654283350 hasConcept C40767141 @default.
- W2654283350 hasConcept C502942594 @default.
- W2654283350 hasConcept C55493867 @default.
- W2654283350 hasConcept C71924100 @default.
- W2654283350 hasConcept C82210918 @default.
- W2654283350 hasConcept C86803240 @default.
- W2654283350 hasConceptScore W2654283350C104317684 @default.
- W2654283350 hasConceptScore W2654283350C159047783 @default.
- W2654283350 hasConceptScore W2654283350C203014093 @default.
- W2654283350 hasConceptScore W2654283350C2522874641 @default.
- W2654283350 hasConceptScore W2654283350C2778227246 @default.
- W2654283350 hasConceptScore W2654283350C2779278377 @default.
- W2654283350 hasConceptScore W2654283350C40767141 @default.
- W2654283350 hasConceptScore W2654283350C502942594 @default.
- W2654283350 hasConceptScore W2654283350C55493867 @default.
- W2654283350 hasConceptScore W2654283350C71924100 @default.
- W2654283350 hasConceptScore W2654283350C82210918 @default.
- W2654283350 hasConceptScore W2654283350C86803240 @default.
- W2654283350 hasLocation W26542833501 @default.
- W2654283350 hasOpenAccess W2654283350 @default.
- W2654283350 hasPrimaryLocation W26542833501 @default.
- W2654283350 hasRelatedWork W1782278359 @default.
- W2654283350 hasRelatedWork W1992483826 @default.
- W2654283350 hasRelatedWork W2039918893 @default.
- W2654283350 hasRelatedWork W2040628940 @default.
- W2654283350 hasRelatedWork W2041875768 @default.
- W2654283350 hasRelatedWork W2128061865 @default.
- W2654283350 hasRelatedWork W2151898635 @default.
- W2654283350 hasRelatedWork W2469326845 @default.
- W2654283350 hasRelatedWork W2548376542 @default.
- W2654283350 hasRelatedWork W2565255091 @default.
- W2654283350 hasRelatedWork W2909256706 @default.
- W2654283350 hasRelatedWork W2955072190 @default.
- W2654283350 hasRelatedWork W3025853129 @default.
- W2654283350 hasRelatedWork W3080204385 @default.
- W2654283350 hasRelatedWork W3096504098 @default.
- W2654283350 hasRelatedWork W3182480385 @default.
- W2654283350 hasRelatedWork W3199073182 @default.
- W2654283350 hasRelatedWork W3214354222 @default.
- W2654283350 hasRelatedWork W785204982 @default.
- W2654283350 hasRelatedWork W3181815315 @default.
- W2654283350 isParatext "false" @default.
- W2654283350 isRetracted "false" @default.
- W2654283350 magId "2654283350" @default.
- W2654283350 workType "article" @default.